Publication at First Faculty of Medicine |
2023
Abstract
Ovarian/fallopian tube cancer is a chronic recurrent disease with an unfavorable prognosis. A new option to improve the prognosis of patients are poly(adenosinediphosphate-ribose) polymerase (PARP) inhibitors, which are used as maintenance therapy after primary treatment or after treatment of platinum-sensitive recurrence.
Niraparib is indicated for all patients in these indications regardless of mutational status. In primary treatment, it significantly prolongs the progression free interval, data with respect to overall survival are not yet mature.